B Group Inc. Invests $2.29 Million in Sight Sciences, Inc. (NASDAQ:SGHT)

B Group Inc. purchased a new stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 629,370 shares of the company's stock, valued at approximately $2,291,000. Sight Sciences makes up 1.4% of B Group Inc.'s holdings, making the stock its 9th biggest holding. B Group Inc. owned about 1.24% of Sight Sciences as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. American Century Companies Inc. grew its holdings in Sight Sciences by 10.7% in the fourth quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock worth $188,000 after purchasing an additional 4,964 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Sight Sciences by 47.6% in the fourth quarter. SG Americas Securities LLC now owns 17,622 shares of the company's stock valued at $64,000 after acquiring an additional 5,681 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Sight Sciences by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock worth $60,000 after buying an additional 5,781 shares in the last quarter. Barclays PLC lifted its stake in Sight Sciences by 11.9% in the 4th quarter. Barclays PLC now owns 56,294 shares of the company's stock worth $205,000 after purchasing an additional 5,994 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Sight Sciences by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 792,860 shares of the company's stock worth $2,887,000 after purchasing an additional 8,731 shares during the last quarter. Institutional investors own 55.51% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Citigroup lowered their target price on Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Piper Sandler dropped their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. UBS Group lowered their target price on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Stifel Nicolaus reduced their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Sight Sciences has an average rating of "Hold" and a consensus target price of $3.83.

Insider Transactions at Sight Sciences

In related news, CEO Paul Badawi sold 24,174 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $55,600.20. Following the transaction, the chief executive officer now owns 6,010,580 shares of the company's stock, valued at approximately $13,824,334. The trade was a 0.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Manohar K. Raheja acquired 10,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the transaction, the executive vice president now owns 145,000 shares of the company's stock, valued at $395,850. This trade represents a 7.41 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 35,196 shares of company stock valued at $81,001 over the last three months. 28.90% of the stock is owned by corporate insiders.

Sight Sciences Stock Down 2.1 %

NASDAQ:SGHT traded down $0.07 during trading hours on Friday, hitting $3.22. The stock had a trading volume of 144,323 shares, compared to its average volume of 209,796. The company has a market cap of $165.29 million, a PE ratio of -3.16 and a beta of 2.46. The business has a 50 day simple moving average of $2.60 and a two-hundred day simple moving average of $3.44. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $8.45.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. Analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.